Thrombocytopenic in a sentence | Use of the word thrombocytopenic examples

By buying the company outright it will now get access to Ablynx’s most promising asset, the experimental drug caplacizumab for treating the blood disease acquired thrombotic thrombocytopenic purpura.

In February, the U.S. Food and Drug Administration approved Ablynx’s most promising asset, the experimental drug caplacizumab for treating the blood disease acquired thrombotic thrombocytopenic purpura.

By buying the company outright it will now get access to Ablynx’s most promising asset, the experimental drug caplacizumab for treating the blood disease acquired thrombotic thrombocytopenic purpura.

After some intense blood work, doctors diagnosed her with thrombotic thrombocytopenic purpura (or TTP), an autoimmune disease that can cause dangerous blood clots to form in the body.

For instance, in idiopathic thrombocytopenic purpura (ITP), the body’s antibodies attack those platelets, which can cause bruises.

Rigel’s Tavalisse was approved to treat patients with immune thrombocytopenic purpura, a disease characterized by excessive bruising and bleeding caused by unusually low levels of platelets, which are integral to clotting.

The condition, called acquired thrombotic thrombocytopenic purpura (aTTP), is a life-threatening, autoimmune disorder characterized by clot formation in small blood vessels throughout the body, cutting off blood supply to various body parts and potentially causing strokes and heart attacks.

“It provides a new treatment option for patients that may reduce recurrences.” Cablivi is already approved in the European Union as a treatment for acquired forms of the disorder, called thrombotic thrombocytopenic purpura.

Promacta has been approved in more than 90 countries as a treatment for low platelet count in patients with chronic immune thrombocytopenic purpura.

The reaction, called immune thrombocytopenic purpura (ITP), has caused three deaths among people infected with Zika in Colombia, one death in Suriname and four deaths during French Polynesia’s 2013-2014 Zika outbreak, reports the Washington Post.

March 22 (Reuters) – Shire Plc: * Shire receives FDA fast track designation for Recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura Source text for Eikon: Further company coverage:

“A few days after his recovery, he returned to the hospital with signs of a bleeding disorder and was diagnosed with immune thrombocytopenic purpura, or ITP,” Sharp said.

Sharp said the man was diagnosed with a rare Zika complication known as immune thrombocytopenic purpura or ITP, an autoimmune disorder in which the immune system attacks blood cells, called platelets.

Jan 30 (Reuters) – Rigel Pharmaceuticals Inc * Rigel Pharmaceuticals announces updates from clinical program of Fostamatinib in patients with chronic immune thrombocytopenic purpura * Rigel Pharmaceuticals says data continue to support co’s plan to submit new drug application to U.S. FDA for Fostamatinib in chronic ITP in Q1 this year * Rigel Pharmaceuticals says chronic ITP patients who respond to Fostamatinib are able to maintain a median platelet count of over 100,000 platelets/ul * Says it now has over 16 months of fit phase 3 data to analyze * Says Fostamatinib study results continue to trend positive Source text for Eikon: Further company coverage:

May 2 (Reuters) – Ablynx Nv: * Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) * A total of 145 patients have been enrolled * Data from this Phase III study will be reported in second half of 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

The condition, called acquired thrombotic thrombocytopenic purpura (aTTP), is a life-threatening, autoimmune disorder characterized by clot formation in small blood vessels throughout the body, cutting off blood supply to various body parts and potentially causing strokes and heart attacks.

“It provides a new treatment option for patients that may reduce recurrences.” Cablivi is already approved in the European Union as a treatment for acquired forms of the disorder, called thrombotic thrombocytopenic purpura.

The main attraction for Novo is Ablynx’s experimental drug caplacizumab for the rare bleeding disorder acquired thrombotic thrombocytopenic purpura, which would complement Novo’s line-up of blood products focused on haemophilia.

Rigel’s Tavalisse was approved to treat patients with immune thrombocytopenic purpura, a disease characterized by excessive bruising and bleeding caused by unusually low levels of platelets, which are integral to clotting.

Last month, the U.S. Food and Drug Administration approved Ablynx’s most promising asset, the experimental drug caplacizumab for treating the blood disease Acquired Thrombotic thrombocytopenic Purpura.

Sanofi is awaiting regulatory approval for Ablynx’s Cablivi (caplacizumab) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), which can be fatal.

The main attraction for Novo is Ablynx’s experimental drug caplacizumab for the rare bleeding disorder acquired thrombotic thrombocytopenic purpura, which would complement Novo’s line-up of blood products focused on haemophilia.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in June had recommended the approval of caplacizumab, which is to be prescribed to adults suffering acquired thrombotic thrombocytopenic purpura (aTTP).

The treatment, called Cablivi, is already approved in the European Union as a treatment for acquired forms of the disorder, called thrombotic thrombocytopenic purpura.

By buying the company outright it will now get access to Ablynx’s most promising asset, the experimental drug caplacizumab for treating the rare bleeding disorder acquired thrombotic thrombocytopenic purpura.

In February, the U.S. Food and Drug Administration approved Ablynx’s most promising asset, the experimental drug caplacizumab for treating the blood disease acquired thrombotic thrombocytopenic purpura.

The condition that killed him, immune thrombocytopenic purpura, is similar to Guillain-Barré in that the Zika infection triggered his immune system to produce antibodies that attacked his own cells.

The condition that killed him, immune thrombocytopenic purpura, is similar to Guillain-Barré in that the Zika infection triggered his immune system to produce antibodies that attacked his own cells.

It occurred in February in a man in his 70s who recovered from Zika but succumbed to immune thrombocytopenic purpura, another type of autoimmune reaction.

The young woman was thrombocytopenic — she had virtually no platelets in her blood.

The hematologist was particularly concerned about thrombotic thrombocytopenic purpura, or T.T.P., a disease in which the clotting system goes wild and starts making abnormal clots in small blood vessels throughout the body.

March 2 (Reuters) – Sanofi Canada: * SANOFI CANADA – CABLIVI APPROVED BY HEALTH CANADA FOR ADULTS LIVING WITH ACQUIRED THROMBOTIC thrombocytopenic PURPURA Source text for Eikon: Further company coverage:

We hope thrombocytopenic in a sentence examples were helpful.